Zhejiang Xianju Pharmaceutical Co Ltd Net Assets
Zhejiang Xianju Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Zhejiang Xianju Pharmaceutical Co Ltd (002332) has net assets worth CN¥6.12 Billion CNY (≈ $895.90 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.27 Billion ≈ $1.06 Billion USD) and total liabilities (CN¥1.14 Billion ≈ $167.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Zhejiang Xianju Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.12 Billion |
| % of Total Assets | 84.27% |
| Annual Growth Rate | 15.54% |
| 5-Year Change | 23.0% |
| 10-Year Change | 171.88% |
| Growth Volatility | 40.18 |
Net Assets of Zhejiang Xianju Pharmaceutical Co Ltd (2006–2025)
Net assets of Zhejiang Xianju Pharmaceutical Co Ltd from 2006 to 2025. This chart illustrates how Zhejiang Xianju Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Zhejiang Xianju Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Zhejiang Xianju Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual net assets of Zhejiang Xianju Pharmaceutical Co Ltd from 2006 to 2025. For live market cap and overall valuation, see 002332 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.08 Billion ≈ $890.00 Million |
+3.29% |
| 2024-12-31 | CN¥5.89 Billion ≈ $861.62 Million |
+1.00% |
| 2023-12-31 | CN¥5.83 Billion ≈ $853.12 Million |
+5.86% |
| 2022-12-31 | CN¥5.51 Billion ≈ $805.91 Million |
+11.38% |
| 2021-12-31 | CN¥4.94 Billion ≈ $723.59 Million |
+7.91% |
| 2020-12-31 | CN¥4.58 Billion ≈ $670.54 Million |
+49.82% |
| 2019-12-31 | CN¥3.06 Billion ≈ $447.57 Million |
+12.85% |
| 2018-12-31 | CN¥2.71 Billion ≈ $396.60 Million |
+13.59% |
| 2017-12-31 | CN¥2.39 Billion ≈ $349.14 Million |
+6.66% |
| 2016-12-31 | CN¥2.24 Billion ≈ $327.35 Million |
+3.92% |
| 2015-12-31 | CN¥2.15 Billion ≈ $314.98 Million |
+75.30% |
| 2014-12-31 | CN¥1.23 Billion ≈ $179.69 Million |
+3.89% |
| 2013-12-31 | CN¥1.18 Billion ≈ $172.97 Million |
-1.71% |
| 2012-12-31 | CN¥1.20 Billion ≈ $175.98 Million |
+4.26% |
| 2011-12-31 | CN¥1.15 Billion ≈ $168.80 Million |
+2.87% |
| 2010-12-31 | CN¥1.12 Billion ≈ $164.09 Million |
+1.93% |
| 2009-12-31 | CN¥1.10 Billion ≈ $160.99 Million |
+171.28% |
| 2008-12-31 | CN¥405.55 Million ≈ $59.34 Million |
+1.18% |
| 2007-12-31 | CN¥400.83 Million ≈ $58.65 Million |
+2.52% |
| 2006-12-31 | CN¥390.97 Million ≈ $57.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Xianju Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3986.2% over the analyzed period, indicating profitable operations and earnings retention.
Zhejiang Xianju Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Zhejiang Xianju Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.65 Billion | 43.91% |
| Other Components | CN¥3.38 Billion | 56.09% |
| Total Equity | CN¥6.04 Billion | 100.00% |
Zhejiang Xianju Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Xianju Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Upwork Inc
NASDAQ:UPWK
|
$1.30 Billion |
|
Altus Group Limited
TO:AIF
|
$1.30 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
$1.30 Billion |
|
Centuria Industrial REIT
AU:CIP
|
$1.30 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
$1.30 Billion |
|
Lotte Rental Co Ltd
KO:089860
|
$1.30 Billion |
|
Shanghai Weaver Network Co Ltd
SHG:603039
|
$1.30 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
$1.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Xianju Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,843,503,305 to 6,035,110,265, a change of 191,606,960 (3.3%).
- Net income of 449,640,395 contributed positively to equity growth.
- Dividend payments of 401,510,861 reduced retained earnings.
- Other factors increased equity by 143,477,426.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥449.64 Million | +7.45% |
| Dividends Paid | CN¥401.51 Million | -6.65% |
| Other Changes | CN¥143.48 Million | +2.38% |
| Total Change | CN¥- | 3.28% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Xianju Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.50x to 1.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.62 | CN¥8.96 | x |
| 2007-12-31 | CN¥0.65 | CN¥8.96 | x |
| 2008-12-31 | CN¥0.65 | CN¥8.96 | x |
| 2009-12-31 | CN¥1.89 | CN¥8.96 | x |
| 2010-12-31 | CN¥1.43 | CN¥8.96 | x |
| 2011-12-31 | CN¥1.46 | CN¥8.96 | x |
| 2012-12-31 | CN¥1.50 | CN¥8.96 | x |
| 2013-12-31 | CN¥1.53 | CN¥8.96 | x |
| 2014-12-31 | CN¥1.57 | CN¥8.96 | x |
| 2015-12-31 | CN¥2.68 | CN¥8.96 | x |
| 2016-12-31 | CN¥2.44 | CN¥8.96 | x |
| 2017-12-31 | CN¥2.62 | CN¥8.96 | x |
| 2018-12-31 | CN¥2.88 | CN¥8.96 | x |
| 2019-12-31 | CN¥3.21 | CN¥8.96 | x |
| 2020-12-31 | CN¥4.49 | CN¥8.96 | x |
| 2021-12-31 | CN¥4.88 | CN¥8.96 | x |
| 2022-12-31 | CN¥5.52 | CN¥8.96 | x |
| 2023-12-31 | CN¥5.86 | CN¥8.96 | x |
| 2024-12-31 | CN¥5.89 | CN¥8.96 | x |
| 2025-12-31 | CN¥6.10 | CN¥8.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Xianju Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.45%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.96%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.20x
- Recent ROE (7.45%) is below the historical average (10.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 13.67% | 6.47% | 0.78x | 2.72x | CN¥13.29 Million |
| 2007 | 17.21% | 6.69% | 0.92x | 2.78x | CN¥27.08 Million |
| 2008 | 17.02% | 5.74% | 0.98x | 3.02x | CN¥26.82 Million |
| 2009 | 8.22% | 6.96% | 0.68x | 1.74x | CN¥-19.26 Million |
| 2010 | 10.86% | 8.01% | 0.82x | 1.65x | CN¥9.55 Million |
| 2011 | 11.87% | 7.87% | 0.84x | 1.80x | CN¥20.95 Million |
| 2012 | 10.35% | 6.05% | 0.82x | 2.10x | CN¥4.10 Million |
| 2013 | 5.24% | 2.62% | 0.84x | 2.38x | CN¥-55.11 Million |
| 2014 | 4.67% | 2.29% | 0.88x | 2.31x | CN¥-64.67 Million |
| 2015 | 4.98% | 4.30% | 0.72x | 1.61x | CN¥-107.47 Million |
| 2016 | 6.57% | 5.84% | 0.69x | 1.63x | CN¥-76.36 Million |
| 2017 | 8.78% | 7.24% | 0.56x | 2.18x | CN¥-28.70 Million |
| 2018 | 11.45% | 8.32% | 0.67x | 2.07x | CN¥38.20 Million |
| 2019 | 13.95% | 11.07% | 0.64x | 1.98x | CN¥116.22 Million |
| 2020 | 11.35% | 12.55% | 0.59x | 1.54x | CN¥60.02 Million |
| 2021 | 12.82% | 14.21% | 0.65x | 1.39x | CN¥136.40 Million |
| 2022 | 13.73% | 17.11% | 0.65x | 1.23x | CN¥203.67 Million |
| 2023 | 9.73% | 13.66% | 0.59x | 1.21x | CN¥-15.53 Million |
| 2024 | 6.80% | 9.93% | 0.57x | 1.20x | CN¥-187.17 Million |
| 2025 | 7.45% | 11.96% | 0.52x | 1.20x | CN¥-153.87 Million |
Industry Comparison
This section compares Zhejiang Xianju Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Xianju Pharmaceutical Co Ltd (002332) | CN¥6.12 Billion | 13.67% | 0.19x | $1.30 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progestero… Read more